126301-19-7

Basic information

• Product Name: Carbamic acid, [1-[[(methylsulfonyl)oxy]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester, (R)-
• CAS NO: 126301-19-7
• Molecular Formula: C15H23NO5S
• Molecular Weight: 329.417
• Mol File: 126301-19-7.mol
• Article Data: 50

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [1-[[(methylsulfonyl)oxy]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester, (R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [1-[[(methylsulfonyl)oxy]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester, (R)-(126301-19-7)
• EPA Substance Registry System: Carbamic acid, [1-[[(methylsulfonyl)oxy]methyl]-2-phenylethyl]-, 1,1-dimethylethyl ester, (R)-(126301-19-7)

Safety Data

• Hazardous Substances Data: 126301-19-7(Hazardous Substances Data)

Upstream product

• 66605-57-0 (S)-N-tert-butoxycarbonyl-2-amino-3-phenylpropanol 
• 7143-01-3 Methanesulfonic anhydride 
• 18942-49-9 Boc-D-Phe-OH 
• 24424-99-5 di-tert-butyl dicarbonate 
• 5267-64-1 (R)-2-amino-3-phenylpropanol 
• 19901-50-9 methyl (2R)-2-(t-butoxycarbonylamino)-3-phenylpropionate 
• 106454-69-7 N-tert-butoxycarbonyl-D-Phenylalaninol 
• 124-63-0 methanesulfonyl chloride 
• 3182-95-4 L-Phenylalaninol 
• 67729-36-6 Boc-Phe-O-COO-isoBu 
• 63-91-2 L-phenylalanine 
• 4522-04-7 ethyl N-{[(1,1-dimethylethyl)oxy]carbonyl}-L-phenylalaninate 
• 119153-87-6 (C₅H₉O₂)C₉H₉NO(O)(CO₂C₂H₅) 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 

Downstream Products

• 126301-23-3 (S)-2-amino-3-phenylpropyl methanesulphonate hydrochloride 
• 126301-28-8 (R)-2-amino-3-phenylpropyl methanesulphonate hydrochloride 
• 122818-32-0 (S)-2-<(tert-Butoxycarbonyl)amino>-3-phenylpropyl thioacetate 
• 126301-32-4 (S)-2-amino-3-phenylpropane-1-sulfonic acid 
• 126301-37-9 (R)-2-amino-3-phenylpropanesulphonic acid 
• 51871-62-6 (S)-3-tert-butoxycarbonylamino-4-phenylbutanoic acid 
• 653589-24-3 (2S)-2-benzyl-4,6-dioxopiperidine 
• 653589-12-9 tert-butyl (2S)-2-benzyl-4,6-dioxo-1-piperidinecarboxylate 
• 68978-89-2 homo-β-phenylalanine methyl ester 
• 130406-33-6 (R)-α-(azidomethyl)-2-phenylethanamine 
• 85612-59-5 (R)-3-phenylpropane-1,2-diamine 
• 1007877-57-7 ((S)-3-Amino-1-benzyl-propyl)-carbamic acid tert-butyl ester 
• 167421-83-2 tert-butyl N-[(1R)-1-methyl-2-phenylethyl]carbamate 
• 146552-72-9 (S)-2-(t-butoxycarbonylamino)-3-phenylpropylamine 

Relevant articles and documents

USP30 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.

Development of Chiral Organosuperbase Catalysts Consisting of Two Different Organobase Functionalities

In the field of chiral Br?nsted base catalysis, a new generation of chiral catalysts has been highly anticipated to overcome the intrinsic limitation of pronucleophiles that are applicable to the enantioselective reactions. Herein, we reveal conceptually new chiral Br?nsted base catalysts consisting of two different organobase functionalities, one of which functions as an organosuperbase and the other as the substrate recognition site. Their prominent activity, which stems from the distinctive cooperative function by the two organobases in a single catalyst molecule, was demonstrated in the unprecedented enantioselective direct Mannich-type reaction of α-phenylthioacetate as a less acidic pronucleophile. The present achievement would provide a new guiding principle for the design and development of chiral Br?nsted base catalysts and significantly broaden the utility of Br?nsted base catalysis in asymmetric organic synthesis.

Synthesis and evaluation of chirally defined side chain variants of 7-chloro-4-aminoquinoline to overcome drug resistance in malaria chemotherapy

A novel 4-aminoquinoline derivative [(S)-7-chloro-N-(4-methyl-1-(4-methyl-piperazin-1-yl)pentan-2-yl)-quinolin-4-amine triphosphate] exhibiting curative activity against chloroquine-resistant malaria parasites has been identified for preclinical development as a blood schizonticidal agent. The lead molecule selected after detailed structure-activity relationship (SAR) studies has good solid-state properties and promising activity against in vitro and in vivo experimental malaria models. The in vitro absorption, distribution, metabolism, and excretion (ADME) parameters indicate a favorable drug-like profile.